Section Arrow
DNTH.NASDAQ
- Dianthus Therapeutics
Quotes are at least 15-min delayed:2026/02/20 04:30 EST
Pre Market
Last
 49.72
0 (0.00%)
Bid
45
Ask
79.55
High 50.72 
Low 48.98 
Volume 278 
Regular Hours (Closed)
Last
 49.72
+2.25 (+4.74%)
Day High 
50 
Prev. Close
47.47 
1-M High
57.5 
Volume 
666.15K 
Bid
45
Ask
79.55
Day Low
46.8 
Open
47.99 
1-M Low
42.7 
Market Cap 
2.05B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 49.05 
20-SMA 50.4 
50-SMA 45.26 
52-W High 57.5 
52-W Low 13.365 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.50/-4.31
Enterprise Value
2.05B
Balance Sheet
Book Value Per Share
12.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.24M
Operating Revenue Per Share
0.15
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
Pre Market 0.1986 +0.0019 +0.97%
IBRXImmunityBio8.61+0.07+0.82%-- 
Pre Market 8.515 -0.095 -1.10%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
Pre Market 1.61 -0.32 -16.58%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
Pre Market 0.1621 -0.0001 -0.06%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
Pre Market 0.23 -0.0083 -3.48%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.